

**Clinical Trial Protocol**

**Title**

**Protocol No:**

**SCC No:**

**Brief Title**

**Other Number(s)**

**Protocol Version – Date**

**Sponsor** Medical Research Council Unit, The Gambia   
PO Box 273 Banjul,   
The Gambia, West Africa

**Principal Investigator**

Signature page

The clinical trial will be carried out in accordance with the protocol, the ICH Harmonised Tripartite Guideline for Good Clinical Practice, <<*insert other regulations if applicable>>*, and in accordance to local legal and regulatory requirements.

|  |  |  |
| --- | --- | --- |
| **Principal Investigator:**    *Name* | **Signature:** | **Date:** |

|  |  |  |
| --- | --- | --- |
| **Sponsor’s representative:**    *Name* | **Signature:** | **Date:** |

Protocol amendment(s)

**Amendment #:**

|  |  |  |
| --- | --- | --- |
| **Principal Investigator:**    Name | **Signature:** | **Date:** |

|  |  |  |
| --- | --- | --- |
| **Sponsor’s representative:**    Name | **Signature:** | **Date:** |

**Table of contents**

Page

[Signature page 2](#_Toc376511436)

[Protocol amendment(s) 3](#_Toc376511437)

[Key roles 6](#_Toc376511438)

[List of abbreviations 7](#_Toc376511439)

[Protocol summary 8](#_Toc376511440)

[1 Background information and rationale 9](#_Toc376511441)

[1.1 Background information 9](#_Toc376511442)

[1.2 Rationale 9](#_Toc376511443)

[1.3 Potential risks and benefits 9](#_Toc376511444)

[2 Study objectives 9](#_Toc376511445)

[2.1 Study endpoints 9](#_Toc376511446)

[3 Study design 9](#_Toc376511447)

[3.1 Type of study and design 9](#_Toc376511448)

[3.2 Randomisation and blinding procedures 9](#_Toc376511449)

[3.2.1 Randomisation 9](#_Toc376511450)

[3.2.2 Blinding 9](#_Toc376511451)

[3.3 Sub-studies 9](#_Toc376511452)

[3.4 Investigational products 10](#_Toc376511453)

[3.4.1 Description of products 10](#_Toc376511454)

[3.4.2 Formulation, packaging and labelling 10](#_Toc376511455)

[3.4.3 Product storage and stability 10](#_Toc376511456)

[3.4.4 Dosage, preparation and administration of investigational products 10](#_Toc376511457)

[3.4.5 Concomitant medications/treatments 10](#_Toc376511458)

[4 Selection and withdrawal of participants 10](#_Toc376511459)

[4.1 Selection of participants 10](#_Toc376511460)

[4.2 Eligibility of participants 10](#_Toc376511461)

[4.2.1 Inclusion criteria 10](#_Toc376511462)

[4.2.2 Exclusion criteria 10](#_Toc376511463)

[4.3 Withdrawal of participants 10](#_Toc376511464)

[5 Study procedures and evaluations 11](#_Toc376511465)

[5.1 Study schedule 11](#_Toc376511466)

[5.1.1 Screening 11](#_Toc376511467)

[5.1.2 Enrollment (Baseline) 11](#_Toc376511468)

[5.1.3 Follow-up 11](#_Toc376511469)

[5.1.4 Final study visit 11](#_Toc376511470)

[5.1.5 Early termination visit 11](#_Toc376511471)

[5.2 Study evaluations 11](#_Toc376511472)

[5.2.1 Clinical evaluations 11](#_Toc376511473)

[5.2.2 Laboratory evaluations 11](#_Toc376511474)

[6 Safety considerations 11](#_Toc376511475)

[6.1 Methods and timing for assessing, recording, and analysing safety parameters 11](#_Toc376511476)

[6.1.1 Adverse events 12](#_Toc376511477)

[6.1.2 Reactogenicity 12](#_Toc376511478)

[6.1.3 Serious adverse events (SAEs) 12](#_Toc376511479)

[6.2 Reporting procedures 12](#_Toc376511480)

[6.3 Safety oversight 12](#_Toc376511481)

[7 Discontinuation criteria 12](#_Toc376511482)

[7.1 Participant’s premature termination 12](#_Toc376511483)

[7.2 Study discontinuation 12](#_Toc376511484)

[8 Statistical considerations 12](#_Toc376511485)

[9 Data handling and record keeping 12](#_Toc376511486)

[9.1 Data management and processing 12](#_Toc376511487)

[9.2 Source documents and access to source data 12](#_Toc376511488)

[9.3 Protocol deviations 13](#_Toc376511489)

[10 Quality control and quality assurance 13](#_Toc376511490)

[10.1 Study monitoring 13](#_Toc376511491)

[11 Ethical considerations 13](#_Toc376511492)

[11.1 General considerations on human subject protection 13](#_Toc376511493)

[11.1.1 Rationale for participant selection 14](#_Toc376511494)

[11.1.2 Evaluation of risks and benefits 14](#_Toc376511495)

[11.2 Informed consent 14](#_Toc376511496)

[11.3 Participant confidentiality 14](#_Toc376511497)

[11.4 Future use of stored specimen 14](#_Toc376511498)

[12 Financing and insurance 14](#_Toc376511499)

[13 Publication policy 14](#_Toc376511500)

[14 References 14](#_Toc376511501)

[Supplements, appendices and other documents 15](#_Toc376511502)

[Appendix: Schedule of events 17](#_Toc376511503)

Key roles

For questions regarding this protocol, contact <<*insert name of appropriate MRC staff>>* at MRC << *insert address, email, phone(s), fax, >>*.

|  |  |
| --- | --- |
| **Author(s):** |  |
| **Sponsor’s representative:** |  |
| **Chief Investigator:** |  |
| **Principal Investigator(s):** |  |
| **Sub-Investigator(s):** |  |
| **Sponsor’s Medical Expert:** |  |
| **Trial monitor(s):** |  |
| **Local Safety Monitor:** |  |
| **Chair of DMC/DMSB:** |  |
| **Statistician:** |  |
| **External Adviser:** |  |
| **Clinical Laboratory/ies:** |  |
| **Other institutions/ Collaborators:** |  |
| **Local Ethics Committee** | Gambia Government/MRC Joint Ethics Committee,  c/o MRC Unit, The Gambia,  PO Box 273, Banjul, The Gambia, West Africa |

List of abbreviations

|  |  |
| --- | --- |
| AE | Adverse Event |
| CRF | Case Report Form |
| DMC | Data Monitoring Committee |
| GCP | Good Clinical Practice |
| ICH | International Conference on Harmonization |
| IEC | Independent Ethics Committee |
| MRC | Medical Research Council; represents Medical Research Council Unit, The Gambia |
| PI | Principal Investigator |

Protocol summary

|  |  |
| --- | --- |
| **Title:** |  |
| **Alias :** |  |
| **Phase**: |  |
| **Population:** |  |
| **Number of participants:** |  |
| **Number of Sites:** |  |
| **Location of Sites (including satellite sites):**  **Trial Duration:**  **- Clinical Phase:**  **- Whole trial:** |  |
| **Duration for Participants:** |  |
| **Description of Investigational Products:** |  |
| **Objectives:** |  |
| **Endpoints:** |  |
| **Description of Study Design:** |  |

# Background information and rationale

## Background information

References of literature and data are listed in Section 14.

## Rationale

## Potential risks and benefits

The potential risks to human subjects and known benefits, if any, are summarised in Section “Human Subject Protection”.

# Study objectives

## Study endpoints

# Study design

## Type of study and design

## Randomisation and blinding procedures

### Randomisation

### Blinding

## Sub-studies

## Investigational products

### Description of products

### Formulation, packaging and labelling

### Product storage and stability

### Dosage, preparation and administration of investigational products

### Concomitant medications/treatments

# Selection and withdrawal of participants

## Selection of participants

## Eligibility of participants

Participants must meet all of the inclusion criteria and none of the exclusion criteria to be eligible to participate in the trial.

### Inclusion criteria

### Exclusion criteria

## Withdrawal of participants

A study participant will be discontinued from participation in the study if:

* Any clinical significant adverse event (AE), laboratory abnormality, intercurrent illness, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant.
* Development of any exclusion criteria.

For further details on participant’s premature termination see corresponding section below.

Participants are free to withdraw from the study at any time without giving a reason.

# Study procedures and evaluations

For an overview see annex “Schedule of Events”.

## Study schedule

### Screening

### Enrollment (Baseline)

### Follow-up

### Final study visit

### Early termination visit

## Study evaluations

### Clinical evaluations

### Laboratory evaluations

# Safety considerations

## Methods and timing for assessing, recording, and analysing safety parameters

### Adverse events

### Reactogenicity

### Serious adverse events (SAEs)

## Reporting procedures

## Safety oversight

# Discontinuation criteria

## Participant’s premature termination

## Study discontinuation

# Statistical considerations

# Data handling and record keeping

## Data management and processing

## Source documents and access to source data

The Principal Investigators will maintain appropriate medical and research records for this study in compliance with the principles of good clinical practice and regulatory and institutional requirements for the protection of confidentiality of participants. The study team members will have access to records.

The authorised representatives of the sponsor, the ethics committee(s) or regulatory bodies may inspect all documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) for the participants in this study. The clinical study site will permit access to such records.

## Protocol deviations

A protocol deviation (PD) is any noncompliance with the clinical trial protocol, good clinical practice (GCP), or other applicable regulatory requirements. The noncompliance may be either on the part of the participant or the investigator including the study team members, and may result in significant added risk to the study participant. As a result of a deviation, corrective actions will be developed and implemented promptly.

If a deviation from, or a change of, the protocol is implemented to eliminate an immediate hazard(s) to trial participant without prior ethics approval, the PI or designee will submit the implemented deviation or change, the reasons for it, and, if appropriate, the proposed protocol amendment(s) as soon as possible to the sponsor for agreement and the relevant independent ethics committee (IEC) for review and approval.

The PI or designee will document and explain any deviation from the approved protocol on the CRF, where appropriate, and record and explain any deviation in a protocol deviation form that will be maintained as an essential document.

# Quality control and quality assurance

## Study monitoring

# Ethical considerations

This study is conducted in accordance with the principles set forth in the ICH Harmonised Tripartite Guideline for Good Clinical Practice and the Declaration of Helsinki in its current version (see appendix), whichever affords the greater protection to the participants.

## General considerations on human subject protection

### Rationale for participant selection

### Evaluation of risks and benefits

## Informed consent

## Participant confidentiality

## Future use of stored specimen

# Financing and insurance

# Publication policy

# References

Supplements, appendices and other documents

**Schematic of Study Design**:

Appendix: Schedule of events

**Appendix:**

**World Medical Association Declaration of Helsinki**

**Ethical Principles for Medical Research Involving Human Subjects**

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964  
and amended by the:  
29th WMA General Assembly, Tokyo, Japan, October 1975  
35th WMA General Assembly, Venice, Italy, October 1983  
41st WMA General Assembly, Hong Kong, September 1989  
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996  
52nd WMA General Assembly, Edinburgh, Scotland, October 2000   
53rd WMA General Assembly, Washington DC, USA, October 2002 (Note of Clarification added)  
55th WMA General Assembly, Tokyo, Japan, October 2004 (Note of Clarification added)  
59th WMA General Assembly, Seoul, Republic of Korea, October 2008  
64th WMA General Assembly, Fortaleza, Brazil, October 2013

**Preamble**

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data.

The Declaration is intended to be read as a whole and each of its constituent paragraphs should be applied with consideration of all other relevant paragraphs.

2. Consistent with the mandate of the WMA, the Declaration is addressed primarily to physicians. The WMA encourages others who are involved in medical research involving human subjects to adopt these principles.

**General Principles**

3. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act in the patient's best interest when providing medical care.”

4. It is the duty of the physician to promote and safeguard the health, well-being and rights of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty.

5. Medical progress is based on research that ultimately must include studies involving human subjects.

6. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments). Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.

7. Medical research is subject to ethical standards that promote and ensure respect for all human subjects and protect their health and rights.

8. While the primary purpose of medical research is to generate new knowledge, this goal can never take precedence over the rights and interests of individual research subjects.

9. It is the duty of physicians who are involved in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects. The responsibility for the protection of research subjects must always rest with the physician or other health care professionals and never with the research subjects, even though they have given consent.

10. Physicians must consider the ethical, legal and regulatory norms and standards for research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for research subjects set forth in this Declaration.

11. Medical research should be conducted in a manner that minimises possible harm to the environment.

12. Medical research involving human subjects must be conducted only by individuals with the appropriate ethics and scientific education, training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional.

13. Groups that are underrepresented in medical research should be provided appropriate access to participation in research.

14. Physicians who combine medical research with medical care should involve their patients in research only to the extent that this is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

15. Appropriate compensation and treatment for subjects who are harmed as a result of participating in research must be ensured.

**Risks, Burdens and Benefits**

16. In medical practice and in medical research, most interventions involve risks and burdens.

Medical research involving human subjects may only be conducted if the importance of the objective outweighs the risks and burdens to the research subjects.

17. All medical research involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and groups involved in the research in comparison with foreseeable benefits to them and to other individuals or groups affected by the condition under investigation.

Measures to minimise the risks must be implemented. The risks must be continuously monitored, assessed and documented by the researcher.

18. Physicians may not be involved in a research study involving human subjects unless they are confident that the risks have been adequately assessed and can be satisfactorily managed.

When the risks are found to outweigh the potential benefits or when there is conclusive proof of definitive outcomes, physicians must assess whether to continue, modify or immediately stop the study.

**Vulnerable Groups and Individuals**

19. Some groups and individuals are particularly vulnerable and may have an increased likelihood of being wronged or of incurring additional harm.

All vulnerable groups and individuals should receive specifically considered protection.

20. Medical research with a vulnerable group is only justified if the research is responsive to the health needs or priorities of this group and the research cannot be carried out in a non-vulnerable group. In addition, this group should stand to benefit from the knowledge, practices or interventions that result from the research.

**Scientific Requirements and Research Protocols**

21. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

22. The design and performance of each research study involving human subjects must be clearly described and justified in a research protocol.

The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, potential conflicts of interest, incentives for subjects and information regarding provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study.

In clinical trials, the protocol must also describe appropriate arrangements for post-trial provisions.

**Research Ethics Committees**

23. The research protocol must be submitted for consideration, comment, guidance and approval to the concerned research ethics committee before the study begins. This committee must be transparent in its functioning, must be independent of the researcher, the sponsor and any other undue influence and must be duly qualified. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration.

The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No amendment to the protocol may be made without consideration and approval by the committee. After the end of the study, the researchers must submit a final report to the committee containing a summary of the study’s findings and conclusions.

**Privacy and Confidentiality**

24. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information.

**Informed Consent**

25. Participation by individuals capable of giving informed consent as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no individual capable of giving informed consent may be enrolled in a research study unless he or she freely agrees.

26. In medical research involving human subjects capable of giving informed consent, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, post-study provisions and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information.

After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

All medical research subjects should be given the option of being informed about the general outcome and results of the study.

27. When seeking informed consent for participation in a research study the physician must be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent must be sought by an appropriately qualified individual who is completely independent of this relationship.

28. For a potential research subject who is incapable of giving informed consent, the physician must seek informed consent from the legally authorised representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the group represented by the potential subject, the research cannot instead be performed with persons capable of providing informed consent, and the research entails only minimal risk and minimal burden.

29. When a potential research subject who is deemed incapable of giving informed consent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorised representative. The potential subject’s dissent should be respected.

30. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research group. In such circumstances the physician must seek informed consent from the legally authorised representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research must be obtained as soon as possible from the subject or a legally authorised representative.

31. The physician must fully inform the patient which aspects of their care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never adversely affect the patient-physician relationship.

32. For medical research using identifiable human material or data, such as research on material or data contained in biobanks or similar repositories, physicians must seek informed consent for its collection, storage and/or reuse. There may be exceptional situations where consent would be impossible or impracticable to obtain for such research. In such situations the research may be done only after consideration and approval of a research ethics committee.

**Use of Placebo**

33. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best proven intervention(s), except in the following circumstances:

Where no proven intervention exists, the use of placebo, or no intervention, is acceptable; or

Where for compelling and scientifically sound methodological reasons the use of any intervention less effective than the best proven one, the use of placebo, or no intervention is necessary to determine the efficacy or safety of an intervention

and the patients who receive any intervention less effective than the best proven one, placebo, or no intervention will not be subject to additional risks of serious or irreversible harm as a result of not receiving the best proven intervention.

Extreme care must be taken to avoid abuse of this option.

**Post-Trial Provisions**

34. In advance of a clinical trial, sponsors, researchers and host country governments should make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial. This information must also be disclosed to participants during the informed consent process.

**Research Registration and Publication and Dissemination of Results**

35. Every research study involving human subjects must be registered in a publicly accessible database before recruitment of the first subject.

36. Researchers, authors, sponsors, editors and publishers all have ethical obligations with regard to the publication and dissemination of the results of research. Researchers have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. All parties should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results must be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest must be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

**Unproven Interventions in Clinical Practice**

37. In the treatment of an individual patient, where proven interventions do not exist or other known interventions have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorised representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. This intervention should subsequently be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information must be recorded and, where appropriate, made publicly available.